Itch is one of the top two reasons dog owners take their pets to the veterinarian.

In fact, 15% of the 150 million dogs in Europe and the United States visit the clinic each year due to an itch problem. There are many causes of itch including atopic dermatitis (AD), allergies, anxiety, infections, and parasites (such as fleas). Like many humans, dogs are increasingly spending more of their lives indoors.  This is correlated with increased incidence of AD and allergic dermatitis, often resulting in difficult-to-manage itch.

Those who have owned a severely itchy dog would likely agree that itch creates a number of problems for dogs and owners alike. In addition to the discomfort felt by dogs, sores can form at the site of scratching and become infected. Constant licking and chewing results in bald patches. In fact,  48% of pet owners reported that the quality of their own lives is decreased when their dog had itch from AD. For example, 35% of owners of AD patients reported disturbed sleep. This increased to 80% when the owners sleep in the same room as their dogs.

Our itch candidate, NCT-10004, acts through a novel CNS-based mechanism. In animal model studies, it significantly reduces itch in both rodents and dogs with a single dose.